Clearmind Medicine Inc. has announced the successful enrollment of patients for the second cohort of its ongoing FDA-approved Phase I/IIa clinical trial evaluating CMND-100, a proprietary oral drug candidate aimed at treating Alcohol Use Disorder (AUD). The company, based in Vancouver, Canada, confirmed the completion of this phase on December 16, 2025, following the rapid recruitment of six participants across three prominent clinical sites: Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
This latest milestone builds on the encouraging results from the first cohort, which demonstrated a favorable safety profile and preliminary signs of reduced cravings and withdrawal symptoms among participants. The swift enrollment of the second group underscores the operational excellence of the collaborating clinical centers, reflecting their commitment to advancing innovative solutions for AUD, a condition that impacts millions of people globally with few effective treatment options.
Trial Progress and Future Expectations
Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind Medicine, expressed enthusiasm about the rapid pace of enrollment, stating, “We are thrilled with the accelerated pace of enrollment for our second cohort, which reflects the high level of interest from both patients and leading clinical sites in CMND-100’s potential to transform AUD treatment.” He added that this progress positions the company favorably to gather additional valuable data that could lead to a breakthrough therapy targeting the underlying causes of addiction while maintaining an improved safety profile.
The multinational Phase I/IIa trial is structured to assess not only the safety and tolerability of CMND-100 but also its pharmacokinetics and preliminary efficacy in patients with moderate to severe AUD. Dosing for the second cohort is anticipated to begin shortly, with topline results expected in the coming months.
About Clearmind Medicine Inc.
Clearmind is focused on the discovery and development of novel psychedelic-derived therapeutics aimed at addressing widespread and underserved health issues, particularly AUD. The company’s intellectual property portfolio includes nineteen patent families and 31 granted patents, with plans to seek additional patents for its compounds as warranted. Clearmind is also open to acquiring further intellectual property to bolster its portfolio.
Shares of Clearmind are publicly traded on the Nasdaq under the symbol “CMND” and on the Frankfurt Stock Exchange under the symbol “CWY0.” For more information, visit the company’s website or contact their investor relations team.
This announcement contains forward-looking statements as defined by the Private Securities Litigation Reform Act. Statements regarding the company’s expectations for treatment advancements and the potential for CMND-100 to transform AUD treatment are based on management’s current beliefs and expectations, which are inherently uncertain. Actual results may differ materially from these projections. For more details concerning risks and uncertainties, stakeholders are encouraged to review the company’s filings with the Securities and Exchange Commission.
